Journal
JOURNAL OF INNOVATIVE OPTICAL HEALTH SCIENCES
Volume 12, Issue 3, Pages -Publisher
WORLD SCIENTIFIC PUBL CO PTE LTD
DOI: 10.1142/S1793545819410037
Keywords
Liposome; photosensitizer; photodynamic therapy; photoacoustic imaging; fluorescence imaging
Funding
- National Basic Research Program of China [2015CB352005]
- National Natural Science Foundation of China [61705139, 61875135, 61525503, 61620106016, 61835009, 81727804]
- Guangdong Natural Science Foundation Innovation Team [2014A030312008, 2017A030310136]
- Shenzhen Basic Research Project, China [JCYJ20150930104948169, JCYJ20160328144 746940, GJHZ20160226202139185, JCYJ20170412105003520, JCYJ20170817094735945, JCYJ20170818090620324]
- Postdoctoral Science Foundation, China [2017M612724]
- University of Macau in Macau [MYRG2016-00110-FHS]
- Macao government [FDCT 0011/2018/A1, FDCT 025/2015/A1]
Ask authors/readers for more resources
The photosensitizer (PS) as photodynamic therapy (PDT) agent, can also serve as the contrast agent for dual-modal fluorescence imaging (FLI) and photoacoustic imaging (PAI) for precise cancer theranostics. In this study, the PAI capability of commercial PS, benzoporphyrin derivative monoacid ring-A (BPD) were examined and compared with that from the other PSs and dyes such as TPPS4, Cy5 dye and ICG. We discovered that BPD exhibited its advantage as contrast agent for PAI. Meanwhile, BPD can also serve as the contrast agent for enhanced FLI. In particular, the PEGylated nanoliposome (PNL) encapsulated BPD (LBPD) was produced for contrast enhanced dual-modal FLI and PAI and imaging-guided high-efficiency PDT. Enhanced FLI and PAI results demonstrated the signifficant accumulation of LBPD both within and among individual tumor during 24 h monitoring for in vivo experiment tests. In-vitro and in-vivo PDT tests were also performed, which showed that LBPD have higher PDT efficiency and can easily break the blood vessel of tumor tissues as compared to that from BPD. It was discovered that LBPD has great potentials as a diagnosis and treatment agent for dual-modal FLI and PAI-guided PDT of cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available